MDH presents 340B findings; lawmakers split over HF3609 changes as roll-call amendments tie MDH presented a second-year transparency report on the federal 340B drug-pricing program, finding program growth, concentration of net revenue among a small number of covered entities, and reporting inconsistencies. Lawmakers debated HF3609 (to preserve 340B access and add reporting); two amendments failed on 11–11 roll calls and the bill was laid over for further work.

Minnesota lawmakers are divided over proposed changes to the crucial 340B drug-pricing program, with heated debates surrounding its future and transparency.

Read the full story

#MN #PharmaceuticalPolicy #HealthcareAccess #MinnesotaHealthcare #CitizenPortal #TransparencyInGovernance

340B overhaul bill draws sharply divided testimony on transparency and costs Second Substitute Senate Bill 59 81 would bar manufacturers or third parties from restricting 340B drug acquisition or conditioning access on data, require hospital and manufacturer reporting, and authorize fines; supporters say it protects the safety net, opponents warn of higher employer/taxpayer costs and litigation risk.

The battle over Second Substitute Senate Bill 59 81 is heating up, pitting community health advocates against pharmaceutical giants in a fight for the future of drug discounts for vulnerable populations.

Get the details!

#WA #PharmaceuticalPolicy #HealthcareAccess #CitizenPortal

Bill would seek distinct Medicaid reimbursement for long‑acting injectables; DHHS raises CMS approval questions Senator John Fredericksen asked DHHS to pursue a state plan amendment to establish separate Medicaid rates for long‑acting injectable and extended‑release medications administered in hospitals and ERs. DHHS said the drugs are already covered but warned federal IMD rules could make a CMS approval unlikely for some institutional settings.

A new bill in Nebraska aims to secure distinct Medicaid reimbursement for long-acting injectables, potentially transforming patient care in emergency settings—yet federal approval remains uncertain.

Learn more here!

#NE #PharmaceuticalPolicy #HealthcareAccess #CitizenPortal #MentalHealthReform

As someone who is frustrated by the inaccuracies in the FDA's NDC product files, I am thrilled to see this in the 2027 proposed rule. I wish this applied to all manufacturers, not just those in the Drug Discount Program
#pharmaceuticalpolicy #healthpolicy #fda #cms @fda.gov

Medical Experts Critique 340B Program for Funding Woke Hospital Initiatives in Kansas Testimony highlights misuse of 340B program funds for ideological goals over patient care.

Kansas lawmakers are raising alarms over the 340B drug pricing program, claiming funds meant for patient care are being diverted to controversial DEI initiatives.

Get the details!

#KS #CitizenPortal #HealthcareAccess #PharmaceuticalPolicy #KansasHospitals #DiversityEquityInclusion

Kansas Committee Hears Testimony on 340B Program and Pharmacy Benefit Managers Legislators discuss the impact and reform of the 340B program and PBMs in Kansas.

Kansas lawmakers are diving deep into the powerful world of pharmaceutical benefit managers, aiming to reshape drug pricing and healthcare for residents.

Click to read more!

#KS #CitizenPortal #PharmaceuticalPolicy #HealthcareReform #KansasPharmaceuticals #LegislativeAccountability

Trump's "Most Favored Nation" Plan Exposes Indian Big Pharma's Concentration Risk New executive order targeting drug prices reveals dangerous US dependency and accelerates the need for market diversification and higher-value products.

2/2 Read an Analysis by Dev Chandrasekhar: Trump's "Most Favored Nation" Plan Exposes Indian Big Pharma's Concentration Risk: basispointinsight.com/Story/Home/t...

#BigPharma #DrugPricing #USIndiaTrade #PharmaceuticalPolicy #Geoeconomics #HealthcareCosts

Under the leadership of Prof. Jillian Kohler (@uoftpharmacy.bsky.social), #JPHSR looks to publish research that identifies the most effective ways to manage, govern, finance and deliver high quality #PharmaceuticalServices to improve #PublicHealth

#PharmaceuticalPolicy

#Pharmacoeconomics

Under the leadership of Prof. Jillian Kohler @uoftpharmacy.bsky.social, #JPHSR publishes research on the most effective ways to manage, govern, finance and deliver high quality #PharmaceuticalServices to improve #PublicHealth.

#PharmaceuticalPolicy
#PharmaceuticalFinancing
#Pharmacoeconomics